Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting
Madryn Asset Management Demands SomaLogic's Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting
Madryn Asset Management Addresses SomaLogic's Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools
SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools
Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools
Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures
Leading Independent Proxy Advisory Firms Glass Lewis and ISS Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools
SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders
Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools
SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure
Madryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of Alternatives
Madryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw “Cautionary Support” for SomaLogic's Value-Destructive Proposed Merger with Standard BioTools
Tikvah Management Announces Intention to Vote against Somalogic's Proposed Merger with Standard BioTools
Madryn Asset Management Reiterates Alternative Path to SomaLogic's Value-Destructive Proposed Merger with Standard BioTools
ISS Recommends SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools
Madryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioTools
SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools
Madryn Asset Management Issues Letter to Shareholders Correcting False and Misleading Statements in SomaLogic's Recent Investor Presentation
Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools
Madryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote “AGAINST” the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioTools
Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools
STANDARD BIOTOOLS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Standard BioTools Inc. - LAB
SomaLogic Inc. (SLGC) Q3 2023 Earnings Call Transcript
SomaLogic announces new SomaScan® 11K Platform
SomaLogic to Announce Third Quarter 2023 Financial Results on November 8, 2023
STANDARD BIOTOOLS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Standard BioTools Inc. - LAB
Why SomaLogic Stock Dived by 10% on Wednesday
LAB INVESTOR ALERT: Julie & Holleman LLP Announces Investigation of Proposed Merger Between Standard BioTools and SomaLogic
SLGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SomaLogic, Inc. Is Fair to Shareholders
Shareholder Alert: Ademi LLP investigates whether SomaLogic, Inc. has obtained a Fair Price in its transaction with Standard BioTools
SomaLogic's stock surges as it agrees to be bought by Standard BioTools in all-stock merger
3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
SomaLogic and Korea's DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market
SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors
SomaLogic expands agreement with Novo Nordisk to 2025
Why Shares of SomaLogic Are Up Tuesday
Somalogic, Inc. (SLGC) Q2 2023 Earnings Call Transcript
SomaLogic Reports Second Quarter 2023 Financial Results
SomaLogic to Announce Second Quarter 2023 Financial Results on August 14, 2023
SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe
SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe
SomaLogic, Inc. (SLGC) Just Flashed Golden Cross Signal: Do You Buy?
SomaLogic, Inc. (SLGC) Q1 2023 Earnings Call Transcript
SomaLogic, Inc. (SLGC) Reports Q1 Loss, Tops Revenue Estimates
SomaLogic to Announce First Quarter 2023 Financial Results on May 11, 2023
SomaLogic, Inc. (SLGC) Q4 2022 Earnings Call Transcript
SomaLogic, Inc. (SLGC) Reports Q4 Loss, Tops Revenue Estimates
SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial Results